Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pimecrolimus

Small molecule · Inhibitor of FKBP-12 (macrophilin-12) (FKBP1A) and calcineurin (PPP3CA) · developed by Bausch

Approved FDA, Dec 2001
2 Registered trials

What is Pimecrolimus?

Pimecrolimus is a calcineurin inhibitor immunosuppressant that binds FKBP-12 and inhibits calcineurin, blocking T-cell activation and the synthesis of several cytokines. It is studied as a topical cream for atopic dermatitis and as an ophthalmic ointment for blepharitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
FKBP-12 (macrophilin-12) (FKBP1A), calcineurin (PPP3CA)
Mechanism
Inhibitor of FKBP-12 (macrophilin-12) (FKBP1A) and calcineurin (PPP3CA)
Pathways
calcineurin-dependent T-cell activation, cytokine synthesis (IL-2, IFN-gamma, IL-4, IL-10), mast cell mediator release
Therapy area
Ophthalmology
Developer
Bausch
In trials of
VTRS
FDA status
Approved (December 13, 2001), NDA021302 · FDA label
UNII
7KYV510875

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06400511 Phase 3 Blepharitis Terminated VTRS
NCT06052995 N/A Mild to Moderate Atopic Dermatitis Active not recruiting VTRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mild to Moderate Atopic DermatitisBlepharitis

Other drugs acting on FKBP1A / PPP3CA

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.